Phase II Study of Belzutifan(MK-6482) in Patients with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of belzutifan (MK-6482) in patients with advanced pheochromocytoma/ paraganglioma (PPGL) or pancreatic neuroendocrine tumors (pNET).
General Information
NCT#: NCT04924075
Study ID: 6482-015
Trial Phase: Phase II
Trial Sponsor: Merck Sharp & Dohme Corp.
Therapies Used in This Trial: Belzutifan